FTC’s new approach puts PBMs in the crosshairs; Biden Covid adviser David Kessler to exit

The FTC is hoping to expand its authority to crack down on unfair business practices, a shift that has implications for its scrutiny of PBMs. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by     Submit your application here to be considered for the 2023 STAT Madness, a bracket-style tournament to find the best innovations in science and medicine. Nominations close this Tuesday. STAT+: With the FTC's more expansive approach to antitrust, PBMs are in the crosshairs By John Wilkerson SAUL LOEB/POOL/AFP via Getty Images The FTC is hoping to expand its authority to crack down on unfair business practices, a shift that has implications for its scrutiny of PBMs. Read More Biden Covid adviser David Kessler to exit as pandemic response winds down By Sarah Owermohle Susan Walsh-Pool/Getty Images David Kessler, the D.C. veteran who guided dispatches of millions of Covid vaccines and treatments, is exiting the Biden administration. Read More STAT+: As Ginkgo stock sinks, CEO Jason Kelly tries to win over drugmakers in San Francisco By Jason Mast and Matthew Herper Ruby Wallau/STAT Under pressure, the CEO has been meeting with dozens of drugmakers in San Francisco to find partners for his synthetic biology platform. Read More Sponsored Insight by STAT Madness Apply for STAT Madness! Has your institution innovated in ways worth celebrating? Submit your application to be considered for our bracket-style tournament to find the best innovations in science and medicine here. STAT+: Biotech startups are hungry for dollars. Here's what one pharma executive was looking for at JPM By Allison DeAngelis Courtesy Bayer The balance of power between biotech startups and big pharma has shifted — but Bayer executive Marianne De Backer is still looking for deals. Read More Opinion: For addiction treatment, longer is better. But insurance companies usually cut it short By Nick Hayes Business Wire Longer engagement is a key to successful addiction treatment. Yet insurance companies tend to approve only short periods of treatment. Read More STAT+: Congressional Medicare advisers warn of higher drug prices, despite new price negotiation By John Wilkerson Adobe The new law directing Medicare to negotiate drug prices may actually increase prices for new drugs, congressional Medicare advisers said. Read More STAT+: Q&A with Carbon Health's Myoung Cha: Why the company is changing course By Mohana Ravindranath AP/Business Wire Carbon Health is in a turbulent time: The primary care tech company has had layoffs and announced plans to dial back major business lines. Read More STAT+: Oscar Health's CEO on post-hype health insurance and finally turning a profit By Bob Herman Noam Galai/Getty Images “Profitability is the number one goal” for this year, Oscar CEO Mario Schlosser told STAT in an interview at #JPM23. Read More Friday, January 13, 2023       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2023, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser